Condition

T-cell Acute Lymphoblastic Leukemia clinical trials and research

• 13Clinical trials
• 5Countries

Newest T-cell Acute Lymphoblastic Leukemia clinical trials

All recruiting trials (13)

• A combination therapy for teens and young adults with relapsed or refractory T-ALL/T-LBL

  This phase 1 study tests a four-drug regimen (venetoclax, dexamethasone, bortezomib, and daratumumab) in adolescents and young adults whose T-cell ALL or T-cell lymphoblastic lymphoma has come back or not responded.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT07513129

• Anti-CCR9 CAR T-cell therapy for T‑cell acute lymphoblastic leukaemia and lymphoblastic lymphoma

  We will try anti-CCR9 CAR T cells made from your own blood to find a dose that is safe for children and adults with relapsed or refractory T‑cell leukaemia or lymphoma.

  Recruiting Phase 1 University College, London · London · NCT07300683

• CD7 CAR T therapy for high-risk T-cell cancers

  This study tests a patient’s own edited T cells, engineered to target CD7, in people with relapsed or high-risk T-cell leukemia or lymphoma.

  Recruiting Phase 1 Baylor College of Medicine · Houston, Texas and 1 other locations · NCT07220993

• Preventing relapse in high-risk T-cell leukemia after stem cell transplant

  This study is testing if a new combination of medications can help prevent relapse in patients with high-risk T-cell leukemia after they have a stem cell transplant.

  Recruiting Phase 2 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT06686108

• Calaspargase pegol, decitabine, and venetoclax combination for relapsed/refractory T-cell ALL and T-LLy in children and young adults

  This treatment tries to see if giving calaspargase pegol and decitabine together with venetoclax can control relapsed or refractory T-ALL and T-LLy in children and young adults.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06561074

• WU-CART-007 anti-CD7 CAR-T for relapsed or MRD-positive T-cell ALL and lymphoblastic lymphoma

  This trial will try WU-CART-007, an off-the-shelf anti-CD7 CAR-T therapy, in people with relapsed/refractory or MRD-positive T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma to see if it produces MRD-negative remissions.

  Recruiting at 18 sites Phase 2 Allotera Therapeutics · Duarte, California and 17 other locations · NCT06514794

• CAR-T cell therapy targeting CD5 and CD7 for T-cell leukemia and lymphoma

  This study is testing a new CAR-T cell therapy for young people with tough-to-treat T-cell leukemia and lymphoma to see if it can help them when other treatments haven't worked.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06420076

• Improving treatment responses in children with T-cell leukemia or lymphoma

  This study is testing if adding two new drugs to standard chemotherapy can help children and young adults with T-cell leukemia or lymphoma have better treatment outcomes.

  Recruiting at 4 sites Phase 2 St. Jude Children's Research Hospital · San Diego, California and 3 other locations · NCT06390319

• CD7 CAR-T therapy for patients with relapsed or refractory T-cell malignancies

  This study is testing a new type of CAR-T therapy for people with T-cell leukemia that hasn't responded to other treatments to see if it can help them feel better.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 3 other locations · NCT06316427

• Evaluating OC-1 Therapy for Patients with Relapsed T-Cell Leukemia and Lymphoma

  This study is testing a new therapy for children and adults with relapsed T-cell leukemia and lymphoma to see if it can help them feel better after other treatments have failed.

  Recruiting at 2 sites Phase 1 OneChain Immunotherapeutics · Barcelona and 1 other locations · NCT05679895

• Combining venetoclax and azacitidine for newly diagnosed T-ALL patients

  This study is testing a new treatment combining venetoclax and azacitidine to see if it helps people aged 15 and older who are newly diagnosed with T-cell acute lymphoblastic leukemia feel better.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT05376111

• Using daratumumab to treat T-cell leukemia that doesn't respond to chemotherapy

  This study is testing if daratumumab can help T-cell leukemia patients who haven't responded to chemotherapy by seeing if it clears their cancer and improves their chances of staying healthy.

  Recruiting Phase 2 Eastern Cooperative Oncology Group · Chicago, Illinois · NCT05289687

• Targeted immunotherapy for high-risk T-cell leukemia and lymphoma in young patients

  This study is testing a new treatment called daratumumab for young patients with high-risk T-cell leukemia and lymphoma to see if it is safe and helps improve their outcomes after a stem cell transplant.

  Recruiting at 8 sites Phase 1 New York Medical College · Phoeniz, Arizona and 15 other locations · NCT04972942

Related topics

Quick answers

How many T-cell Acute Lymphoblastic Leukemia clinical trials are recruiting right now?

13, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 5 countries. The most sites are in United States (7 trials), China (4 trials), Australia (1 trial), United Kingdom (1 trial), Spain (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 6, Phase 1: 5, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →